A method of validating patient-specific oligos for use in multiplexed patient-specific assays, the method comprising: extracting DNA or RNA from a patient sample to produce a DNA or RNA sample; introducing a plurality of sets of spike-in sequences into the DNA or RNA sample to produce a spiked sample, wherein the plurality of sets of spike-in sequences comprises spike-in sequences of known concentrations; cosynthesizing synthesis-control oligos and the patient-specific oligos; and assaying the spiked sample with the synthesis-control oligos to produce a read out of the counts of the sets of spike-in sequences; and comparing the counts of the sets of spike-in sequences with the known concentrations of the spike-in sequences, wherein the limit of detection and the dynamic range for the patient-specific oligos are validated when the counts from the sets of spike-in sequences correspond to the known concentrations of the spike-in sequences, wherein a set of spike-in sequences comprises: a unique reference sequence; and a plurality of near-neighbor sequences, wherein each near-neighbor sequence comprises at least one substitution, insertion, and/or deletion compared to the reference sequence and the concentration of each near-neighbor sequence is less than the concentration of the reference sequence; and wherein reading out the counts of spike-in sequences determines the dose-response characteristics of the synthesis-control oligos, which act as proxies for those of the patient-specific oligos in the assay and provide a quality control check for batch synthesis of the patient-specific oligos. extracting DNA or RNA from a patient sample to produce a DNA or RNA sample; introducing a plurality of sets of spike-in sequences into the DNA or RNA sample to produce a spiked sample, wherein the plurality of sets of spike-in sequences comprises spike-in sequences of known concentrations; cosynthesizing synthesis-control oligos and the patient-specific oligos; and assaying the spiked sample with the synthesis-control oligos to produce a read out of the counts of the sets of spike-in sequences; and comparing the counts of the sets of spike-in sequences with the known concentrations of the spike-in sequences, wherein the limit of detection and the dynamic range for the patient-specific oligos are validated when the counts from the sets of spike-in sequences correspond to the known concentrations of the spike-in sequences, wherein a set of spike-in sequences comprises: a unique reference sequence; and a plurality of near-neighbor sequences, wherein each near-neighbor sequence comprises at least one substitution, insertion, and/or deletion compared to the reference sequence and the concentration of each near-neighbor sequence is less than the concentration of the reference sequence; and a unique reference sequence; and a plurality of near-neighbor sequences, wherein each near-neighbor sequence comprises at least one substitution, insertion, and/or deletion compared to the reference sequence and the concentration of each near-neighbor sequence is less than the concentration of the reference sequence; and wherein reading out the counts of spike-in sequences determines the dose-response characteristics of the synthesis-control oligos, which act as proxies for those of the patient-specific oligos in the assay and provide a quality control check for batch synthesis of the patient-specific oligos.